Laura M Smeaton1, Deborah Kacanek1, Kateryna Mykhalchenko2, Kristine Coughlin3, Karin L Klingman4, Susan L Koletar5, Elizabeth Barr6, Ann C Collier7. 1. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 2. Department of Family Medicine, BronxCare Health, Bronx, New York, USA. 3. Frontier Science and Technology Research Foundation, Inc, Amherst, New York, USA. 4. Division of Acquired Immune Deficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 5. Division of Infectious Diseases, The Ohio State University, Columbus, Ohio, USA. 6. AIDS Clinical Trials Group Community Scientific Subcommittee, Baltimore, Maryland, USA. 7. Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
BACKGROUND: Women are underrepresented in human immunodeficiency virus (HIV) research in the United States. To determine if women screening for HIV clinical trials enrolled at lower rates than men, we performed a retrospective, cross-trial analysis. METHODS: We conducted an analysis of screening and enrollment during 2003-2013 to 31 clinical trials at 99 AIDS Clinical Trials Group network research sites in the United States. Random-effects meta regression estimated whether sex differences in not enrolling ("screen out") varied by various individual, trial, or site characteristics. RESULTS: Of 10 744 persons screened, 18.9% were women. The percentages of women and men who screened out were 27.9% and 26.5%, respectively (P = .19); this small difference did not significantly vary by race, ethnicity, or age group. Most common reasons for screening out were not meeting eligibility criteria (30-35%) and opting out (23%), and these did not differ by sex. Trial and research site characteristics associated with variable screen-out by sex included HIV research domain and type of hemoglobin eligibility criterion, but individual associations did not persist after adjustment for multiple testing. CONCLUSIONS: In the absence of evidence of significantly higher trial screen-out for women, approaching more women to screen may increase female representation in HIV trials.
BACKGROUND:Women are underrepresented in human immunodeficiency virus (HIV) research in the United States. To determine if women screening for HIV clinical trials enrolled at lower rates than men, we performed a retrospective, cross-trial analysis. METHODS: We conducted an analysis of screening and enrollment during 2003-2013 to 31 clinical trials at 99 AIDS Clinical Trials Group network research sites in the United States. Random-effects meta regression estimated whether sex differences in not enrolling ("screen out") varied by various individual, trial, or site characteristics. RESULTS: Of 10 744 persons screened, 18.9% were women. The percentages of women and men who screened out were 27.9% and 26.5%, respectively (P = .19); this small difference did not significantly vary by race, ethnicity, or age group. Most common reasons for screening out were not meeting eligibility criteria (30-35%) and opting out (23%), and these did not differ by sex. Trial and research site characteristics associated with variable screen-out by sex included HIV research domain and type of hemoglobin eligibility criterion, but individual associations did not persist after adjustment for multiple testing. CONCLUSIONS: In the absence of evidence of significantly higher trial screen-out for women, approaching more women to screen may increase female representation in HIV trials.
Authors: Guoxing Greg Soon; Min Min; Kimberly A Struble; Kirk M Chan-Tack; Thomas Hammerstrom; Karen Qi; Susan Zhou; Rafia Bhore; Jeffrey S Murray; Debra B Birnkrant Journal: AIDS Patient Care STDS Date: 2012-06-26 Impact factor: 5.078
Authors: Sara H Bares; Laura M Smeaton; Ai Xu; Catherine Godfrey; Grace A McComsey Journal: J Womens Health (Larchmt) Date: 2018-04-02 Impact factor: 2.681
Authors: Kathleen Squires; Linda-Gail Bekker; Christine Katlama; Yazdan Yazdanpanah; Yan Zhou; Anthony J Rodgers; Mark J DiNubile; Peter A Sklar; Randi Y Leavitt; Hedy Teppler Journal: Open Forum Infect Dis Date: 2017-02-28 Impact factor: 3.835
Authors: Kathleen E Squires; Benjamin Young; Lizette Santiago; Robin H Dretler; Sharon L Walmsley; Henry H Zhao; Gary E Pakes; Lisa L Ross; Mark S Shaefer Journal: HIV AIDS (Auckl) Date: 2017-03-03
Authors: Karine Dubé; Lara Hosey; Kate Starr; Liz Barr; David Evans; Erin Hoffman; Danielle M Campbell; Jane Simoni; Jeremy Sugarman; John Sauceda; Brandon Brown; Karen L Diepstra; Catherine Godfrey; Daniel R Kuritzkes; David A Wohl; Rajesh Gandhi; Eileen Scully Journal: AIDS Res Hum Retroviruses Date: 2020-04 Impact factor: 2.205
Authors: Laura M Smeaton; Emma M Kileel; Beatriz Grinsztejn; Edward M Gardner; Kate Starr; Melissa L Murry; Patrice Desvigne-Nickens; Beverly Alston-Smith; Myron A Waclawiw; Katharine Cooper-Arnold; José V Madruga; Shashi Sangle; Kathleen V Fitch; Markella V Zanni; Pamela S Douglas; Heather J Ribaudo; Steven K Grinspoon; Karin L Klingman Journal: J Infect Dis Date: 2020-07-09 Impact factor: 5.226
Authors: Karine Dubé; John Kanazawa; Chadwick Campbell; Cheriko A Boone; Allysha C Maragh-Bass; Danielle M Campbell; Moisés Agosto-Rosario; Jamila K Stockman; Dázon Dixon Diallo; Tonia Poteat; Mallory Johnson; Parya Saberi; John A Sauceda Journal: AIDS Res Hum Retroviruses Date: 2021-05-31 Impact factor: 2.205
Authors: Elizabeth Barr; Karine Dubé; Shobha Swaminathan; Carlos Del Rio; Danielle M Campbell; Marta Paez-Quinde; Susan E Cohn Journal: HIV Res Clin Pract Date: 2021-06-18